A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

NCT04959981 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG: ERAS-007
DRUG: ERAS-601
DRUG: Osimertinib
DRUG: Sotorasib

Sponsor

Erasca, Inc.